1. Slamon, D.J., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783–792 (2001)
2. Plosker, G.L., et al.: Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66(4), 449–475 (2006)
3. Department of Health and Ageing, Schedule of Pharmaceutical Benefits, Effective 1 January 2012–29 February 2012. 2012, DoHA: Canberra
4. National Institute for Health and Clinical Excellence, Guidance on the use of trastuzumab for the treatment of advanced breast cancer, Technology Appraisal No. 34. 2002, NICE: London
5. Pharmaceutical Benefits Advisory Committee, Public Summary Document, Trastuzumab, powder for IV infusion, 150 mg, Herceptin. November 2008, Department of Health and Ageing: Canberra